## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 10.7% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-10.4% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($53.58)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. HC Wainwright & Co. Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation**
- Source: Nasdaq | 20251203T050229 | Neutral | Relevance: 98%
-  HC Wainwright & Co. has reiterated a Buy recommendation for Arrowhead Pharmaceuticals (ARWR) with an average one-year price target of $50.53/share, despite a projected decrease of 10.17% from its current price. The company's projected annual revenue is 410MM, a 50.51% decrease, and the non-GAAP EPS is expected to be -1.33. Institutional ownership of ARWR increased by 4.57% to 130,072K shares, and the put/call ratio of 0.32 suggests a bullish outlook.

**2. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry**
- Source: Simply Wall Street | 20251203T050228 | Neutral | Relevance: 97%
-  Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw a 33% stock increase last month, culminating in a 116% rise over the past year, yet its price-to-sales (P/S) ratio of 9.2x remains below the industry average. Despite strong past revenue growth, future revenue is projected to contract by 14% annually, contrasting sharply with the broader biotech industry's anticipated 128% annual expansion. This outlook contributes to its modest P/S ratio, suggesting investors are cautious about future growth prospects.

**3. Arrowhead Pharmaceuticals Poised for Growth Following Breakthrough FDA Approvals**
- Source: StocksToTrade | 20251204T050229 | Bullish | Relevance: 96%
- Arrowhead Pharmaceuticals (ARWR) has seen significant growth following breakthroughs including an FDA Breakthrough Therapy designation for plozasiran and a milestone payment from Sarepta. The company reported a substantial revenue increase to $829.4M and a net profit of $30.1M, reversing previous losses. These developments, along with strategic collaborations, have boosted investor confidence and analyst price targets, positioning ARWR for continued expansion in the biopharmaceutical sector.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |
| 2025-12-01 | Chardan Capital | $60 | $60 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |
| 2025-12-01 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($1.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Elevated short interest (11.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +37%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -30% YoY, concerning. Analyst sentiment positive (8 raises, avg +37%). Insider selling cluster ($1.6M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.29 |
| 52W Range | $9.57 - $71.50 |
| Short Interest | 11.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 21.0% to 10.7% (-10.4% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (10.7% > 6.0%), caution on chasing. MRS_5 at 0.1% confirms short-term momentum alignment. Outperforming sector by 13.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.96), confirming momentum. RSI overbought at 71, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 10.66% (CS: 98) | Strong |
| RSI_14 | 70.6 | Overbought |
| MACD Histogram | 1.96 | Bullish |
| vs SMA20 | 1.294x | Above |
| vs SMA50 | 1.480x | Above |
| vs SMA200 | 2.609x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $61.44
- **Stop Loss:** $53.58 (12.8% risk)
- **Target:** $69.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 63
- **Position Value:** $3,870.72
- **Portfolio %:** 3.87%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*